%0 Journal Article
%A López-García, M Ángeles
%A Carretero-Barrio, Irene
%A Pérez-Míes, Belén
%A Chiva, Miguel
%A Castilla, Carolina
%A Vieites, Begoña
%A Palacios, José
%T Low Prevalence of HER2-Positive Breast Carcinomas among Screening Detected Breast Cancers.
%D 2020
%@ 2072-6694
%U https://hdl.handle.net/10668/27491
%X Conflicting results have been reported regarding the prevalence of screen-detected human epidermal growth factor receptor 2 (HER2)-positive breast carcinomas and non-screen detected HER2-positive breast carcinomas. To address this issue, we evaluated the prevalence of HER2-positive breast carcinomas in two independent regional screening programs in Spain. The clinicopathologic and immunohistochemical characteristics of 479 (306 and 173) screen-detected breast carcinomas and 819 (479 and 340) non-screen-detected breast carcinomas diagnosed in women between 50 and 69-year-olds were compared. The prevalence of HER2-positive breast carcinomas was 8.8% and 6.4% in the two series of screen-detected tumors, compared with 16.4% and 13% in non-screen-detected carcinomas. These differences were statistically significant. This lower prevalence of HER2-positive in-screen-detected breast carcinomas was observed in both hormone receptor positive (luminal HER2) and hormone-receptor-negative (HER2 enriched) tumors. In addition, a lower prevalence of triple-negative and a higher prevalence of luminal-A breast carcinomas was observed in screen-detected tumors. Moreover, a literature review pointed out important differences in subrogate molecular types in screen-detected breast carcinomas among reported series, mainly due to study design, technical issues and racial differences.
%K HER2
%K breast cancer
%K estrogen receptor
%K luminal
%K progesterone receptor
%K screening
%K triple negative
%~